HER2 Antibody Clone: GR011 Concentrate
- Known as:
- HER2 Antibody Clone: GR011 Concentrate
- Catalog number:
- 61-0154-2
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Genemed
- Gene target:
- HER2 Antibody Clone: GR011 Concentrate
Related genes to: HER2 Antibody Clone: GR011 Concentrate
- Gene:
- ERBB2 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 2
- Previous symbol:
- NGL
- Synonyms:
- NEU, HER-2, CD340, HER2
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: HER2 Antibody Clone: GR011 Concentrate
Related articles to: HER2 Antibody Clone: GR011 Concentrate
- Molecular profiling is increasingly required for treatment selection in advanced biliary tract cancer, yet tumor tissue is often insufficient and plasma circulating tumor DNA has limited yield. Because bile directly contacts the biliary epithelium and is obtainable during routine biliary interventions, bile cell-free DNA (cfDNA) may provide a tumor-proximal molecular profiling source. - Source: PubMed
Publication date: 2026/08/13
Jang Jun-HaLee Gi YeonChun Jung WonPark Sang-JaeMyung Seung-KwonKong Sun-Young - HER2 represents an actionable target in a subset of biliary tract cancers (BTCs), particularly extrahepatic cholangiocarcinoma (eCCA) and gallbladder carcinoma (GBC). Recent approval of zanidatamab for HER2-positive BTC has further highlighted the clinical relevance of accurate HER2 assessment. - Source: PubMed
Publication date: 2026/08/14
Angerilli ValentinaGasparello JessicaNiero MoniaZanatta LuciaCeccon CarlottaSabbadin MariannaMorana GiovanniBoscolo AliceBortolotti MarcoFavaretto AdolfoDalla Bona EnricoScopellitti MicheleZanus GiacomoFassan Matteo - Gastric carcinoma is the fifth-most common cancer worldwide and the third-leading cause of cancer-related deaths, with a 5-year survival rate of approximately 20%. Human epidermal growth factor receptor 2 (HER2) overexpression occurs in 10-30% of gastric and gastroesophageal junction adenocarcinomas and acts as a key prognostic and predictive biomarker, similar to breast cancer. Encoded by the ERBB2 gene, HER2 is a transmembrane tyrosine kinase receptor that promotes cell proliferation, survival, and differentiation via phosphoinositide 3-kinase/AKT and mitogen-activated protein kinase pathways. In gastric cancer, HER2 expression is often heterogeneous and incomplete, which complicates diagnostics and is linked to aggressive features such as intestinal histology, advanced stage, and poor survival. HER2 positivity rates show geographic variation (12.5-13.8% in Euro-Latin American cohorts) and higher prevalence in proximal tumors and chromosomal instability-high subtypes. - Source: PubMed
Publication date: 2026/08/14
Gaur Shivam S B SharmaPatil Shilpa TAmar Thumma - Vepdegestrant is an investigational, orally administered PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader being evaluated for the treatment of ER+/HER2- advanced breast cancer, with promising results in prior studies of Western and Japanese patients. Vepdegestrant had not been previously evaluated in Chinese patients. - Source: PubMed
Publication date: 2026/08/13
Xu BingheYang JinZhang PinWang WennaZhang LiangZhao Xiao'aiGuan FeiChen NaihanZhao HuadongFei Cong - HER2-mutant non-small cell lung cancer (NSCLC) comprises molecularly heterogeneous tumors with diverse ERBB2 mutation subtypes, and HER2-directed therapies have increased the need for refined molecular stratification. However, subtype-specific co-occurring genomic alterations remain incompletely characterized. We performed a two-stage clinicogenomic analysis to identify and validate recurrent co-mutations in HER2-mutant NSCLC. A public MSK-IMPACT lung adenocarcinoma cohort was used for discovery, and a nationwide Japanese real-world cohort from the Center for Cancer Genomics and Advanced Therapeutics was used for validation. In the MSK-IMPACT cohort of 2201 lung adenocarcinomas, TERT mutations were significantly enriched in ERBB2-mutant tumors compared with ERBB2-wild-type tumors (odds ratio, 2.40; 95% confidence interval, 1.12-4.70; p = 0.017). This association was reproduced in the independent validation cohort, where 16 of 174 HER2-mutant NSCLC cases harbored concurrent TERT mutations, all of which were promoter-region variants. Among the evaluated clinicogenomic variables, the ERBB2 mutation subtype was the only factor significantly associated with TERT mutation status. The ERBB2 G776-altered subtype remained independently associated with TERT mutation after multivariable adjustment (adjusted odds ratio, 7.49; 95% confidence interval, 1.81-31.0; p = 0.006). In a small exploratory subset of trastuzumab deruxtecan-treated patients (n = 52; TERT-mutated, n = 5), no statistically robust differences in treatment outcomes were observed according to TERT mutation status. TERT promoter mutations are recurrent co-mutations in HER2-mutant NSCLC and are preferentially associated with the ERBB2 G776-altered subgroup. These findings support ERBB2 subtype-aware molecular stratification and highlight previously underappreciated genomic heterogeneity within HER2-mutant NSCLC. - Source: PubMed
Publication date: 2026/08/13
Yoshimura AkihiroYoshida JuichiroTakumi ChiekoTakayama Koichi